Investigational drug · Phase 2
ST-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Pain.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "ST-01"
First trial start
2023
Mar 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ST-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Pain
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "ST-01" as an intervention, largest first.
- Sustained Release Lidocaine for the Treatment of Postoperative PainPivotal-lookingRecruiting
University of British ColumbiaAcademic, hospital or other
NCT05193227 · 120 participants (planned) · Start Oct 27, 2021 · Primary completion Apr 27, 2026
Drug: ST-01; Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®) · For: Postoperative Pain; Postsurgical Pain
Sites: Vancouver, Canada · 2 sites in all
Sustained Therapeutics Inc.Industry
NCT05707208 · 63 participants · Start Mar 21, 2023 · Primary completion Dec 4, 2025
Drug: ST-01; 1% Lidocaine HCL · For: Chronic Pain
Sites: Calgary, Canada; Kelowna, Canada; Vancouver, Canada · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.
Ismail M, Al-Gizey N, Alabed Z, et al. · Pharmaceuticals (Basel) 2026
- Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
Qi C, Liu C, Peng Z, et al. · Lancet 2025
- Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials.
Qi C, Zhang P, Liu C, et al. · J Clin Oncol 2024
- Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
Qi C, Chong X, Zhou T, et al. · Chin J Cancer Res 2024
- Crystallinity swayed phase transformation and oxygen vacancy formation in TiO2 aerogel photocatalysts.
Hiremath V, Heo J, Park HH, et al. · Environ Res 2023
- A phase 1 study of an injectable lidocaine paste for spermatic cord block in men with chronic scrotal content pain.
Witherspoon LDE, Kesch C, Schmitt V, et al. · Can Urol Assoc J 2023
Also in development for Chronic Pain
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- LY4065967Phase 23 trials
Eli Lilly · Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.